Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | PKLR | P30613 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280156 | 0.81 | PKM (0.70) | PKMGAACA1CA2MMP13 | |
| SCHEMBL11986371 | 0.81 | PKM (0.70) | PKMGAACA1CA2MMP13 | |
| SCHEMBL368040 | 0.79 | PKM (0.67) | PKMGAACA1CA2MMP13 | |
| SCHEMBL24010097 | 0.78 | PKM (0.59) | PKMGAACA1CA2MMP13 | |
| SCHEMBL4541426 | 0.78 | PKM (0.73) | PKMGAACA1CA2MMP13 | |
| SCHEMBL14486413 | 0.78 | PKM (1.00) | PKMGAACA1CA2MMP13 | |
| SCHEMBL835692 | 0.78 | PKM (1.00) | PKMGAACA1CA2MMP13 | |
| SCHEMBL13074716 | 0.78 | PKM (1.00) | PKMGAACA1CA2MMP13 | |
| SCHEMBL8427813 | 0.78 | PKM (0.73) | PKMGAACA1CA2MMP13 | |
| SCHEMBL19864931 | 0.78 | CA1 (0.65) | PKMGAACA1CA2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112390697-B | Synthesis method of N-arylselenium/thioethyl sulfoxide imine | 成都理工大学 | 2023-03-10 | — | — | CN | claimed |
| CN-112390697-A | Synthesis method of N-arylselenium/thioethyl sulfoxide imine | 成都理工大学 | 2021-02-23 | — | — | CN | claimed |
| CN-110526847-B | Synthesis method of N-aryl sulfuryl sulfoxide imine | 成都理工大学 | 2021-01-19 | — | — | CN | claimed |
| WO-2025073057-A1 | METHODS FOR PREPARING SULFILIMINES AND SULFOXIMINES FROM THIOETHERS USING O-(DIPHENYLPHOSPHINYL)HYDROXYL AMINE (DPPH), AND AMATOXIN ANALOGS PREPARED FROM SUCH METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-04-10 | — | — | WO | disclosed |
| CN-119604487-A | Novel sulfimide derivative or pharmaceutically acceptable salt thereof and application thereof | 韩国科学技术研究院 | 2025-03-11 | — | — | CN | disclosed |
| WO-2023234759-A1 | NOVEL SULFANONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 한국과학기술연구원 | 2023-12-07 | — | — | WO | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-112390697-B | Synthesis method of N-arylselenium/thioethyl sulfoxide imine | 成都理工大学 | 2023-03-10 | — | — | CN | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008061236-A2 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20060217353-A1 | 24-sulfoximine vitamin D3 compounds | CYTOCHROMA INC. (CA) | 2006-09-28 | — | — | US | disclosed |
| EP-1511725-A1 | 24-SULFOXIMINE VITAMIN D sb 3 /sb COMPOUNDS | Johns Hopkins University (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003106411-A1 | 24-SULFOXIMINE VITAMIN D3 COMPOUNDS | JOHNS HOPKINS UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-4556413-A | POSTEMERGENCE AND PREEMERGENCE HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0109575-A2 | Benzoic-acid derivatives, process and means for its production | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | PKM 2565/4885GAA 997/4885CA1 4178/4885 |
| US-20060217353-A1 | 24-sulfoximine vitamin D3 compounds | CYP24A1, CYP2R1, CYP27B1 | PKM 4255/4885GAA 2265/4885CA1 3533/4885 |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | SRC, PTK2B, TYRO3 | PKM 1057/4885GAA 3138/4885CA1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.